Latest news
29 September 2020
Touchlight Genetics and Stonehaven Incubate form Touchlight Aquaculture
London, England / Andermatt, Switzerland – 29 September 2020 Touchlight Genetics LLC and Stonehaven Incubate AG have formed a new joint venture company, Touchlight Aquaculture LLC, to combine expertise, intellectual property and platform technology. The new company will utilize Touchlight Genetics’ innovative DNA-based Doggybonetm platform to develop new vaccine solutions, focused on providing solutions exclusively … Continued
21 August 2020
Touchlight announces development of a vaccine against COVID-19
Hampton, London, UK – 21 August 2020 Touchlight is pleased to announce it has begun development of a vaccine against SARS-CoV-2 (COVID-19). Bringing together Touchlight’s technology with a team of vaccine development and infectious and respiratory disease experts, this program seeks to augment the existing vaccine development landscape, guided by emerging clinical data and the … Continued
29 July 2020
Cancer Research UK, University of Southampton and Touchlight Genetics Partner to develop head and neck cancer vaccine
Hampton, London, Southampton, UK – 29 July 2020 Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC). HNSCC is the … Continued
18 June 2020
Touchlight to develop biobatteries with potential to address limitations of portable power supply
Hampton, UK – 18 June 2020 – Supported by the Office of Naval Research Global (ONR Global) and the Defense Science and Technology Laboratory (DSTL), Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, is working together with the Minteer Lab, University of Utah, to develop a DNA-enabled biobattery that could … Continued
5 June 2020
Touchlights’s chairman to help lead UK COVID-19 vaccine effort
Dr. Clive Dix appointed as Deputy Head of the UK’s Vaccine Taskforce Hampton, UK – 5 June 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today commented on the news that its Chairman, Dr. Clive Dix, has been appointed Deputy Chair of the UK’s Vaccine Taskforce. In this … Continued
27 April 2020
Touchlight appoints Dr. Helen Horton as Chief Research Officer
Former J&J Senior Scientific Director and immunology expert joins at a pivotal time Touchlight driving its dbDNA technology towards clinical development in therapeutic and prophylactic vaccines Hampton, UK – 27 April 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of Dr. Helen Horton as … Continued
17 January 2019
Touchlight welcomes Anjum Ahmad as Chief Financial Officer
Anjum Ahmad brings extensive insight in the UK’s life sciences sector having been the longstanding Group Finance Director of Touchstone Innovations Plc (formerly Imperial Innovations) – the AIM listed venture capital investor in early stage science. In his former role at Touchstone he was one of the four-person senior executive team, presenting over £200m of … Continued
18 November 2018
Touchlight appoints Dr. Michael Linden as Chief Scientific Officer
Touchlight Genetics Ltd, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announced the appointment of Dr. Michael Linden as Chief Scientific Officer (CSO). In his role Dr. Linden will be responsible for leading the Company’s discovery pipeline and translational research efforts in genetic medicine, deploying their doggybone DNA technology … Continued
2 November 2018
Touchlight awarded runner-up in Spectator Economic Disruptor Award
Earlier this year, The Spectator and Julius Baer launched the inaugural Economic Disruptor Awards to celebrate the most creative entrepreneurs in the UK. Over the past six months, over 100 nominations have been reviewed. On the 1st of November, the winners were announced at a gala dinner hosted by Andrew Neil, Chairman of The Spectator, and attended by … Continued
24 October 2018
Touchlight announces collaboration with Janssen Biotech
Hampton, London, United Kingdom, 23rd October 2018 Touchlight Genetics Ltd., a biotechnology company developing a novel, synthetic DNA vector platform known as “doggybone” DNA, announced a collaboration with Janssen Biotech, Inc. to evaluate the application of doggybone DNA in the development of multiple genetic therapies, in the fields of infectious disease and oncology. The agreement … Continued
27 March 2018
Touchlight opens GMP production facility
Touchlight Genetics Ltd has established a GMP facility to support development of therapeutic products that incorporate the company’s revolutionary dbDNA™ vector technology. The facility will support clinical and commercial production for both in-house and partnered programs. Touchlight has developed a revolutionary DNA vector known as doggybone™ DNA (dbDNA) which enables uniquely differentiated products across multiple … Continued
6 December 2017
Touchlight cited in life sciences sector deal
Today, the UK government has announced that they have agreed with the life sciences sector a transformative new Sector Deal as a part of the Industrial Strategy. The Life Sciences Sector Deal will help ensure new pioneering treatments and medical technologies are produced in the UK, improving patient lives and driving economic growth. The deal … Continued